Business Context and Reporting Period
Company: Gilead Sciences, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2006
Business Overview: Gilead is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutics for life-threatening infectious diseases. Key products include HIV treatments (Truvada, Viread, Emtriva), Hepatitis B treatment (Hepsera), and antifungal therapy (AmBisome). The company also earns significant royalties from partners like Roche (Tamiflu) and Eyetech (Macugen).
Key Financial Metrics
| Metric (in thousands) | Q1 2006 | Q1 2005 |
|---|---|---|
| Total Revenues | $692,878 | $430,414 |
| Net Income | $262,704 | $157,113 |
| Diluted EPS | $0.55 | $0.34 |
| Operating Cash Flow | $221,894 | $222,826 |
| Cash & Marketable Securities | $2,539,621 | $2,311,033 (Dec 31, 2005) |
| Long-Term Debt | $184,000 | $240,000 (Dec 31, 2005) |
| Product Gross Margin | 84% | 86% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 61% year-over-year, driven by a 40% increase in product sales and a 342% surge in royalty and contract revenue.
- HIV Product Sales: HIV product sales rose 50% to $450.7 million. Truvada sales grew 173% to $248.9 million, while Viread sales declined slightly by 3% to $191.8 million due to patient switching to Truvada.
- Royalty Revenue: Royalty revenue jumped to $133.5 million, primarily due to $115.3 million in Tamiflu royalties from Roche, reflecting strong Q4 2005 sales and the elimination of a contractual cost of goods adjustment.
- Expense Increases: Operating expenses increased significantly due to the adoption of SFAS 123R (stock-based compensation), which added $29.6 million in expenses. SG&A expenses rose 80% to $142.5 million, and R&D expenses rose 26% to $88.4 million.
- Debt Reduction: The company repaid $56.0 million of its term loan during the quarter, reducing long-term debt from $240 million to $184 million.
Guidance, Outlook, and Risks
- 2006 Guidance:
- HIV Product Sales: Expected range of $1.825 billion to $1.875 billion (excludes potential single tablet regimen).
- AmBisome Sales: Expected range of $205.0 million to $215.0 million.
- Hepsera Sales: Expected range of $205.0 million to $215.0 million.
- R&D Expenses: Expected range of $345.0 million to $370.0 million.
- SG&A Expenses: Expected range of $500.0 million to $530.0 million.
- Effective Tax Rate: Expected range of 33% to 35%.
- Management Commentary: Management highlighted strong uptake of Truvada in Europe and the U.S. They noted the filing of a New Drug Application (NDA) in April 2006 for a single tablet regimen combining Truvada and BMS's Sustiva. The company also discontinued development of its internal integrase inhibitor GS 9160 due to bioavailability issues.
- Subsequent Events: In April 2006, Gilead issued $1.3 billion in convertible senior notes and repurchased $544.9 million of its common stock. The company also invested $25 million in Corus Pharma.
- Risks: Key risks include dependence on HIV products (65% of revenue), competition from GSK and others, potential compulsory licensing of patents (specifically in Brazil), and reimbursement pressures in Europe. Legal proceedings regarding Medicaid pricing and securities litigation remain ongoing.
Investor Verification Checklist
- Accounting Change Impact: Verify the full-year impact of SFAS 123R adoption on net income and EPS, as this significantly increased Q1 expenses.
- Single Tablet Regimen: Monitor the FDA approval status of the Truvada/Sustiva single tablet regimen, as its launch could alter gross margins and revenue recognition.
- Debt Structure: Review the terms of the $1.3 billion convertible notes issued in April 2006 and the associated hedging strategies to understand potential dilution.
- Patent Challenges: Track developments regarding compulsory licensing threats in Brazil and patent challenges in Asia for Hepsera.
- European Distribution: Assess the outcome of negotiations to terminate distribution relationships in certain European markets and associated termination costs.